#BEGIN_DRUGCARD DB02926

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
30915

# Chemical_Formula:
C5H6O5

# Chemical_IUPAC_Name:
2-oxopentanedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-Oxo-Glutaric Acid

# HET_ID:
AKG

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H6O5/c6-3(5(9)10)1-2-4(7)8/h1-2H2,(H,7,8)(H,9,10)

# InChI_Key:
InChIKey=KPGXRSRHYNQIFN-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2926

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
146.0981

# Molecular_Weight_Mono:
146.021523302

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1AIB
1MZF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.6

# Predicted_LogS:
-0.44

# Predicted_Water_Solubility:
5.31e+01 g/l

# Primary_Accession_No:
DB02926

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
51

# PubChem_Substance_ID:
46506957

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
DB03806
EXPT00137

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)CCC(=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:39 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X03629

# Drug_Target_1_GenBank_ID_Protein:
41011

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
aspC

# Drug_Target_1_Gene_Sequence:
>1191 bp
ATGTTTGAGAACATTACCGCCGCTCCTGCCGACCCGATTCTGGGCCTGGCCGATCTGTTT
CGTGCCGATGAACGTCCCGGCAAAATTAACCTCGGGATTGGTGTCTATAAAGATGAGACG
GGCAAAACCCCGGTACTGACCAGCGTGAAAAAGGCTGAACAGTATCTGCTCGAAAATGAA
ACCACCAAAAATTACCTCGGCATTGACGGCATCCCTGAATTTGGTCGCTGCACTCAGGAA
CTGCTGTTTGGTAAAGGTAGCGCCCTGATCAATGACAAACGTGCTCGCACGGCACAGACT
CCGGGGGGCACTGGCGCACTACGCGTGGCTGCCGATTTCCTGGCAAAAAATACCAGCGTT
AAGCGTGTGTGGGTGAGCAACCCAAGCTGGCCGAACCATAAGAGCGTCTTTAACTCTGCA
GGTCTGGAAGTTCGTGAATACGCTTATTATGATGCGGAAAATCACACTCTTGACTTCGAT
GCACTGATTAACAGCCTGAATGAAGCTCAGGCTGGCGACGTAGTGCTGTTCCATGGCTGC
TGCCATAACCCAACCGGTATCGACCCTACGCTGGAACAATGGCAAACACTGGCACAACTC
TCCGTTGAGAAAGGCTGGTTACCGCTGTTTGACTTCGCTTACCAGGGTTTTGCCCGTGGT
CTGGAAGAAGATGCTGAAGGACTGCGCGCTTTCGCGGCTATGCATAAAGAGCTGATTGTT
GCCAGTTCCTACTCTAAAAACTTTGGCCTGTACAACGAGCGTGTTGGCGCTTGTACTCTG
GTTGCTGCCGACAGTGAAACCGTTGATCGCGCATTCAGCCAAATGAAAGCGGCGATTCGC
GCTAACTACTCTAACCCACCAGCACACGGCGCTTCTGTTGTTGCCACCATCCTGAGCAAC
GATGCGTTACGTGCGATTTGGGAACAAGAGCTGACTGATATGCGCCAGCGTATTCAGCGT
ATGCGTCAGTTGTTCGTCAATACGCTGCAGGAAAAAGGCGCAAACCGCGACTTCAGCTTT
ATCATCAAACAGAACGGCATGTTCTCCTTCAGTGGCCTGACAAAAGAACAAGTGCTGCGT
CTGCGCGAAGAGTTTGGCGTATATGCGGTTGCTTCTGGTCGCGTAAATGTGGCCGGGATG
ACACCAGATAACATGGCTCCGCTGTGCGAAGCGATTGTGGCAGTGCTGTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
1868057	Inoue K, Kuramitsu S, Okamoto A, Hirotsu K, Higuchi T, Kagamiyama H: Site-directed mutagenesis of Escherichia coli aspartate aminotransferase: role of Tyr70 in the catalytic processes. Biochemistry. 1991 Aug 6;30(31):7796-801.
1993208	Danishefsky AT, Onnufer JJ, Petsko GA, Ringe D: Activity and structure of the active-site mutants R386Y and R386F of Escherichia coli aspartate aminotransferase. Biochemistry. 1991 Feb 19;30(7):1980-5.
2007566	Yano T, Kuramitsu S, Tanase S, Morino Y, Hiromi K, Kagamiyama H: The role of His143 in the catalytic mechanism of Escherichia coli aspartate aminotransferase. J Biol Chem. 1991 Apr 5;266(10):6079-85.
2513875	Smith DL, Almo SC, Toney MD, Ringe D: 2.8-A-resolution crystal structure of an active-site mutant of aspartate aminotransferase from Escherichia coli. Biochemistry. 1989 Oct 3;28(20):8161-7.
3298240	Kondo K, Wakabayashi S, Kagamiyama H: Structural studies on aspartate aminotransferase from Escherichia coli. Covalent structure. J Biol Chem. 1987 Jun 25;262(18):8648-57.
3521591	Fotheringham IG, Dacey SA, Taylor PP, Smith TJ, Hunter MG, Finlay ME, Primrose SB, Parker DM, Edwards RM: The cloning and sequence analysis of the aspC and tyrB genes from Escherichia coli K12. Comparison of the primary structures of the aspartate aminotransferase and aromatic aminotransferase of E. coli with those of the pig aspartate aminotransferase isoenzymes. Biochem J. 1986 Mar 15;234(3):593-604.
3897210	Kuramitsu S, Okuno S, Ogawa T, Ogawa H, Kagamiyama H: Aspartate aminotransferase of Escherichia coli: nucleotide sequence of the aspC gene. J Biochem (Tokyo). 1985 Apr;97(4):1259-62.
6378205	Kondo K, Wakabayashi S, Yagi T, Kagamiyama H: The complete amino acid sequence of aspartate aminotransferase from Escherichia coli: sequence comparison with pig isoenzymes. Biochem Biophys Res Commun. 1984 Jul 18;122(1):62-7.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9891001	Oue S, Okamoto A, Yano T, Kagamiyama H: Redesigning the substrate specificity of an enzyme by cumulative effects of the mutations of non-active site residues. J Biol Chem. 1999 Jan 22;274(4):2344-9.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2249

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
43574

# Drug_Target_1_Name:
Aspartate aminotransferase

# Drug_Target_1_Number_of_Residues:
396

# Drug_Target_1_PDB_ID:
1CQ8

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_1_Protein_Sequence:
>Aspartate aminotransferase
MFENITAAPADPILGLADLFRADERPGKINLGIGVYKDETGKTPVLTSVKKAEQYLLENE
TTKNYLGIDGIPEFGRCTQELLFGKGSALINDKRARTAQTPGGTGALRVAADFLAKNTSV
KRVWVSNPSWPNHKSVFNSAGLEVREYAYYDAENHTLDFDALINSLNEAQAGDVVLFHGC
CHNPTGIDPTLEQWQTLAQLSVEKGWLPLFDFAYQGFARGLEEDAEGLRAFAAMHKELIV
ASSYSKNFGLYNERVGACTLVAADSETVDRAFSQMKAAIRANYSNPPAHGASVVATILSN
DALRAIWEQELTDMRQRIQRMRQLFVNTLQEKGANRDFSFIIKQNGMFSFSGLTKEQVLR
LREEFGVYAVASGRVNVAGMTPDNMAPLCEAIVAVL

# Drug_Target_1_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_1_SwissProt_ID:
P00509

# Drug_Target_1_SwissProt_Name:
AAT_ECOLI

# Drug_Target_1_Synonyms:
ASPAT
EC 2.6.1.1
Transaminase A

# Drug_Target_1_Theoretical_pI:
5.50

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U17224

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
carC

# Drug_Target_2_Gene_Sequence:
>822 bp
ATGAGCGAAATAGTGAAGTTTAATCCGGTCATGGCATCCGGTTTTGGCGCGTATATCGAT
CATCGGGACTTTCTCGAAGCCAAGACAGAAACGATTAAAAACTTACTGATGCGTCAGGGA
TTTGTCGTGGTCAAAAATCTCGATATTGATAGTGACACATTCCGCGATATCTACTCGGCT
TACGGTACGATCGTGGAGTATGCGGATGAAAAGATCGGCGTAGGTTTCGGCTATCGCGAT
ACGTTGAAGCTGGAAGGGGAAAAAGGAAAAATCGTTACCGGACGTGGTCAACTTCCTTTC
CACGCTGATGGCGGCCTGCTGCTGTCACAGGTAGATCAGGTTTTCCTCTACGCGGCCGAG
ATTAAAAACGTCAAATTCCGTGGTGCAACAACGGTATGCGACCATGCTCTGGCTTGTCAG
GAAATGCCGGCTCACCTTCTGCGCGTACTGGAAGAGGAAACGTTCGAAGTTCGTGTGCTA
GAGCGGGGCTATTACGTGGATGTTTCACCAGACGGTTGGTTCAAGGTGCCGGTCTTCACC
GATCTGGGATGGGTCAGAAAGATGCTGATTTATTTCCCATTTGACGAAGGACAACCGGCT
AGCTGGGAGCCGCGGATTGTCGGTTTCACCGATCATGAAACCCAGGCATTCTTCCAGGAA
CTCGGGGCGTTTTTAAAACAGCCACGCTACTACTACAAACACTTCTGGGAAGATGGTGAC
CTGCTGATTATGGACAACCGTCGTGTCATTCATGAGCGTGAAGAGTTTAACGATGACGAC
ATCGTACGTCGTCTGTATCGCGGACAAACCGCCGATATCTAA

# Drug_Target_2_General_Function:
Involved in oxidoreductase activity

# Drug_Target_2_General_References:
12611886	Clifton IJ, Doan LX, Sleeman MC, Topf M, Suzuki H, Wilmouth RC, Schofield CJ: Crystal structure of carbapenem synthase (CarC). J Biol Chem. 2003 Jun 6;278(23):20843-50. Epub 2003 Feb 28.
9402024	McGowan SJ, Sebaihia M, O'Leary S, Hardie KR, Williams P, Stewart GS, Bycroft BW, Salmond GP: Analysis of the carbapenem gene cluster of Erwinia carotovora: definition of the antibiotic biosynthetic genes and evidence for a novel beta-lactam resistance mechanism. Mol Microbiol. 1997 Nov;26(3):545-56.
9614345	McGowan SJ, Bycroft BW, Salmond GP: Bacterial production of carbapenems and clavams: evolution of beta-lactam antibiotic pathways. Trends Microbiol. 1998 May;6(5):203-8.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4835

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
31611

# Drug_Target_2_Name:
CarC

# Drug_Target_2_Number_of_Residues:
273

# Drug_Target_2_PDB_ID:
1NX8

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF02668	TauD

# Drug_Target_2_Protein_Sequence:
>CarC
MSEIVKFNPVMASGFGAYIDHRDFLEAKTETIKNLLMRQGFVVVKNLDIDSDTFRDIYSA
YGTIVEYADEKIGVGFGYRDTLKLEGEKGKIVTGRGQLPFHADGGLLLSQVDQVFLYAAE
IKNVKFRGATTVCDHALACQEMPAHLLRVLEEETFEVRVLERGYYVDVSPDGWFKVPVFT
DLGWVRKMLIYFPFDEGQPASWEPRIVGFTDHETQAFFQELGAFLKQPRYYYKHFWEDGD
LLIMDNRRVIHEREEFNDDDIVRRLYRGQTADI

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q9XB59

# Drug_Target_2_SwissProt_Name:
Q9XB59_ERWCA

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
4.81

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X92480

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
gltS

# Drug_Target_3_Gene_Sequence:
>4674 bp
ATGTCCTTCCAATATCCGTTGCTAGCTCCTATGACAAACTCCTCTGTTGCCACCAATTCT
AACCAACCATTCCTTGGTCAACCTTGGTTAGTGGAAGAACGAGATGCCTGTGGTGTGGGT
TTTATTGCCAATCTCCGGGGTAAGCCGGACCATACCCTGGTGGAGCAGGCCCTAAAGGCT
CTGGGGTGTATGGAACATCGGGGGGGATGCAGTGCCGATAACGATTCAGGGGACGGGGCC
GGGGTGATGACCGCCATTCCTCGGGAACTACTGGCCCAGTGGTTTAACACCCGCAATTTG
CCCATGCCCGATGGCGATCGACTGGGGGTGGGAATGGTATTTTTACCCCAGGAACCCTCC
GCTAGGGAAGTGGCCCGGGCCTACGTAGAAGAAGTGGTACGGCTGGAAAAATTAACAGTG
TTAGGGTGGCGGGAAGTGCCCGTTAATTCTGATGTGCTGGGCATTCAAGCCAAAAATAAT
CAGCCCCACATTGAACAAATTTTAGTTACTTGTCCCGAAGGTTGTGCCGGAGATGAATTA
GATCGGCGATTGTACATTGCCCGCTCCATCATTGGTAAAAAATTAGCGGAAGATTTCTAC
GTTTGTTCCTTTTCCTGTCGCACCATTGTCTATAAAGGCATGGTCCGGAGCATTATTCTG
GGGGAATTTTATTTAGATTTAAAAAATCCTGGATATACCAGTAATTTCGCCGTTTACCAC
CGTCGTTTCAGCACCAATACCATGCCCAAATGGCCCCTGGCTCAACCCATGCGGCTATTG
GGTCATAACGGGGAAATTAATACCCTTTTAGGCAATATTAATTGGATGGCGGCCAGGGAA
AAAGAATTGGAAGTGTCGGGCTGGACAAAGGCGGAGTTAGAAGCATTAACTCCTATTGTT
AACCAAGCCAACAGTGATTCCTATAACCTTGATAGTGCCCTGGAATTGTTGGTGCGTACT
GGCCGCAGTCCCCTAGAAGCGGCGATGATTTTAGTGCCGGAAGCTTATAAAAATCAGCCA
GCTTTAAAAGATTACCCGGAAATTAGTGATTTCCATGACTACTACAGCGGTTTACAGGAA
CCCTGGGATGGCCCCGCTTTATTAGTATTTAGTGACGGCAAAATTGTTGGCGCTGGGCTA
GACCGGAATGGTTTACGGCCCGCCCGTTATTGCATTACCAAAGATGACTATATTGTCTTG
GGTTCCGAAGCGGGAGTCGTGGATTTACCGGAAGTAGATATTGTTGAAAAAGGTCGCCTA
GCACCGGGGCAAATGATTGCGGTGGATTTGGCTGAGCAAAAAATTCTCAAAAACTATCAA
ATTAAACAGCAGGCGGCCCAAAAATATCCCTATGGGGAATGGATAAAAATCCAGCGTCAA
ACGGTAGCTTCTGATAGCTTTGCTGAAAAAACTTTATTCAATGACGCTCAAACTGTACTG
CAACAACAGGCAGCTTTTGGCTACACCGCTCAAGATGTGGAAATGGTAGTGGTACCCATG
GCCAGCCAAGGTAAGGAACCAACTTTTTGCATGGGGGACGATACGCCCTTAGCTGTACTA
TCCCATAAACCCCGCTTACTGTACGACTATTTCAAACAGCGCTTTGCCCAGGTGACCAAT
CCCCCCATTGATCCTCTGCGGGAAAATTTGGTCATGTCCCTAGCTATGTTTTTAGGCAAA
CGGGGCAATTTGTTAGAGCCTAAAGCGAATCCGCGCCGGACGATTAAACTCCGATCGCCA
TTGGTCAATGAAGTAGAGTTACAGGCCATTAAAACTGGACAGTTGCAGGTGGCAGAAGTT
TCTACCCTTTACGATCTAGATGGGGTGAATAGTCTGGAAACCGCCTTAGATAATTTAGTT
AAAACGGCGATCGCCACTGTGCAAGCCGGGGCAGAAATCTTGGTTTTAACTGATCGTCCT
AACCGGCGCAATATTGGACTGAGAATCAAAGTTTTTATTCCCCCCTTGTTGGCAGTGGAA
GCAGTACATCACCATCTAATTCGGGCCGGGCTAAGGCTAAAAGCGTCCCTAATTGTGGAC
ACCGCCCAGTGTTGGAGTACCCATCATTTTGCCTGCTTGGTAGGCTATGGTGCTTCGGCC
ATTTGTCCCTACCTAGCGTTGGAATCCGTGCGGCAATGGTGGTTAGATGAAAAGACCCAA
AAGCTGATGGAAAATGGGCGCTTGGATCGGATTGACTTACCCACGGCGCTGAAGAATTAT
CGCCAATCCGTGGAAGCAGGATTATTTAAAATTCTCTCCAAAATGGGCATTTCCCTGCTG
GCTTCCTACCACGGTGCCCAAATCTTCGAGGCGATCGGTTTAGGGGCGGAATTGGTGGAA
TATGCCTTTGCTGGAACTACCAGTCGGGTGGGCGGTTTGACCATCGCTGATGTGGCCGGG
GAAGTAATGGTTTTCCATGGCATGGCCTTCCCGGAAATGGCTAAGAAGTTAGAGAACTTT
GGCTTTGTCAACTACCGTCCCGGCGGAGAATATCACATGAACTCGCCGGAGATGTCCAAG
TCTCTCCATAAGGCAGTGGCAGCCTACAAAGTGGGCGGTAATGGTAACAATGGGGAAGCC
TATGACCATTACGAGTTGTACCGTCAATATCTCAAAGACCGTCCTGTCACTGCCCTGCGG
GATTTGCTCGATTTCAATGCAGACCAACCGGCCATTTCCTTAGAAGAAGTGGAATCGGTG
GAAAGTATTGTCAAGCGCTTCTGTACTGGCGGTATGTCCCTCGGTGCGTTGTCCCGGGAA
GCCCATGAAACCTTGGCGATCGCCATGAATCGTTTAGGAGCTAAATCCAATTCCGGGGAA
CCCCCAGAAGATGTAGTACGTTACCTCACTCTAGATGATGTGGATAGCGAAGGAAATTCC
CCCACCTTGCCCCATCTCCACGGCCTGCAAAATGGAGACACGGCCAACTCCGCCATTAAG
CAAATTGCCTCCGGTCGTTTTGGGGTTACCCCGGAATATTTGATGAGTGGCAAACAGTTG
GAAATTAAAATGGCCCAGGGTGCTAAACCTGGGGAAGGGGGGCAGTTACCAGGCAAAAAA
GTCAGTGAATATATTGCCATGTTGCGCCGTTCTAAACCCGGTGTAACCCTCATTTCTCCG
CCGCCCCACCATGACATTTACTCCATCGAAGATTTAGCCCAATTAATTTACGATCTCCTA
CAAATCAATCCCGAAGCCCAGGTATCGGTGAAATTGGTGGCGGAAATTGGTATTGGTACG
ATCGCCGCTGGGGTTGCTAAGGCCAATGCGGATATTATCCAAATTTCTGGCCATGACGGT
GGTACAGGGGCATCACCTTTAAGCTCCATTAAACACGCTGGTTCTCCCTGGGAGCTTGGT
GTTACGGAAGTGCATCGGGTGTTAATGGAAAACCAACTGCGCGATCGGGTTTTGCTGCGG
GCTGATGGTGGTCTGAAAACCGGTTGGGACGTAGTGATGGCCGCCCTTATGGGAGCGGAG
GAGTATGGCTTTGGCTCCATTGCCATGATTGCCGAAGGTTGCATTATGGCCCGGGTTTGC
CACACTAATAATTGTCCCGTCGGGGTTGCCACCCAGCAAGAACGGTTACGGCAACGCTTT
AAAGGAGTGCCGGGGCAGGTGGTTAATTTCTTCTATTTCATTGCCGAGGAAGTGCGCTCC
CTGTTGGCCCATTTAGGTTATCGCAGTTTGGACGACATCATTGGCCGCACTGATCTACTC
AAAGTTCGCTCCGATGTCCAGTTGAGCAAAACCCAGAATCTGACCTTAGATTGTCTGTTA
AATTTGCCCGACACGAAGCAAAACCGGCAATGGTTAAATCACGAACCAGTCCACAGCAAC
GGCCCAGTGTTGGACGACGACATTTTGGCCGACCCTGACATCCAAAGGAAAGCCATTAAC
CATCAAACCACTGCGACCAAAACCTATCGGCTGGACAATACCGACCGCACTGTGGGCACC
CGTCTCTCCGGGTCGATCGCGAAAAAGTATGGCAACAATGGTTTTGAAGGTAACATTACC
CTCAACTTCCAAGGCGCCGCTGGTCAGAGTTTTGGTGCCTTTAACCTGGATGGCATGACC
CTACATCTGCAAGGGGAAGCCAACGACTATGTGGGCAAAGGCATGAATGGGGGTGAAATT
GTCATCGTGCCCCATCCCCAGGCGAGCTTTGCACCGGAAGACAATGTAATTATTGGTAAC
ACCTGTCTCTATGGAGCGACGGGGGGCAACCTTTATGCCAACGGCCGGGCGGGGGAACGC
TTTGCAGTGCGTAACTCCGTGGGTAAAGCCGTGATTGAAGGAGCTGGCGATCACTGTTGT
GAATATATGACCGGTGGCGTGATTGTCGTCCTTGGCCCTGTGGGTCGGAACGTTGGTGCT
GGCATGACTGGTGGTTTGGCTTACTTCCTCGATGAAGTAGGGGATTTACCAGAAAAAATC
AACCCGGAAATCATCACCTTGCAAAGGATCACAGCTTCTAAAGGGGAGGAACAATTGAAA
TCCTTGATTACTGCCCACGTTGAACACACAGGTAGCCCAAAAGGCAAGGCAATTCTGGCT
AACTGGTCCGATTATCTCGGCAAATTCTGGCAGGCCCCTCCTTCCGAAAAAGACTCTCCT
GAAGCCAATGGGGATGTCAGCTTAACCGGGGAGAAGACACTGACCTCTGTCTAG

# Drug_Target_3_General_Function:
Involved in catalytic activity

# Drug_Target_3_General_References:
7727752	Navarro F, Chavez S, Candau P, Florencio FJ: Existence of two ferredoxin-glutamate synthases in the cyanobacterium Synechocystis sp. PCC 6803. Isolation and insertional inactivation of gltB and gltS genes. Plant Mol Biol. 1995 Feb;27(4):753-67.
8905231	Kaneko T, Sato S, Kotani H, Tanaka A, Asamizu E, Nakamura Y, Miyajima N, Hirosawa M, Sugiura M, Sasamoto S, Kimura T, Hosouchi T, Matsuno A, Muraki A, Nakazaki N, Naruo K, Okumura S, Shimpo S, Takeuchi C, Wada T, Watanabe A, Yamada M, Yasuda M, Tabata S: Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. DNA Res. 1996 Jun 30;3(3):109-36.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4836

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
169501

# Drug_Target_3_Name:
Ferredoxin-dependent glutamate synthase 2

# Drug_Target_3_Number_of_Residues:
1556

# Drug_Target_3_PDB_ID:
1OFE

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00310	GATase_2
PF01493	GXGXG
PF01645	Glu_synthase
PF04898	Glu_syn_central

# Drug_Target_3_Protein_Sequence:
>Ferredoxin-dependent glutamate synthase 2
MSFQYPLLAPMTNSSVATNSNQPFLGQPWLVEERDACGVGFIANLRGKPDHTLVEQALKA
LGCMEHRGGCSADNDSGDGAGVMTAIPRELLAQWFNTRNLPMPDGDRLGVGMVFLPQEPS
AREVARAYVEEVVRLEKLTVLGWREVPVNSDVLGIQAKNNQPHIEQILVTCPEGCAGDEL
DRRLYIARSIIGKKLAEDFYVCSFSCRTIVYKGMVRSIILGEFYLDLKNPGYTSNFAVYH
RRFSTNTMPKWPLAQPMRLLGHNGEINTLLGNINWMAAREKELEVSGWTKAELEALTPIV
NQANSDSYNLDSALELLVRTGRSPLEAAMILVPEAYKNQPALKDYPEISDFHDYYSGLQE
PWDGPALLVFSDGKIVGAGLDRNGLRPARYCITKDDYIVLGSEAGVVDLPEVDIVEKGRL
APGQMIAVDLAEQKILKNYQIKQQAAQKYPYGEWIKIQRQTVASDSFAEKTLFNDAQTVL
QQQAAFGYTAEDVEMVVVPMASQGKEPTFCMGDDTPLAVLSHKPRLLYDYFKQRFAQVTN
PPIDPLRENLVMSLAMFLGKRGNLLEPKAESARTIKLRSPLVNEVELQAIKTGQLQVAEV
STLYDLDGVNSLETALDNLVKTAIATVQAGAEILVLTDRPNGAILTENQSFIPPLLAVGA
VHHHLIRAGLRLKASLIVDTAQCWSTHHFACLVGYGASAICPYLALESVRQWWLDEKTQK
LMENGRLDRIDLPTALKNYRQSVEAGLFKILSKMGISLLASYHGAQIFEAIGLGAELVEY
AFAGTTSRVGGLTIADVAGEVMVFHGMAFPEMAKKLENFGFVNYRPGGEYHMNSPEMSKS
LHKAVAAYKVGGNGNNGEAYDHYELYRQYLKDRPVTALRDLLDFNADQPAISLEEVESVE
SIVKRFCTGGMSLGALSREAHETLAIAMNRLGAKSNSGEGGEDVVRYLTLDDVDSEGNSP
TLPHLHGLQNGDTANSAIKQIASGRFGVTPEYLMSGKQLEIKMAQGAKPGEGGQLPGKKV
SEYIAMLRRSKPGVTLISPPPHHDIYSIEDLAQLIYDLHQINPEAQVSVKLVAEIGIGTI
AAGVAKANADIIQISGHDGGTGASPLSSIKHAGSPWELGVTEVHRVLMENQLRDRVLLRA
DGGLKTGWDVVMAALMGAEEYGFGSIAMIAEGCIMARVCHTNNCPVGVATQQERLRQRFK
GVPGQVVNFFYFIAEEVRSLLAHLGYRSLDDIIGRTDLLKVRSDVQLSKTQNLTLDCLLN
LPDTKQNRQWLNHEPVHSNGPVLDDDILADPDIQEAINHQTTATKTYRLVNTDRTVGTRL
SGAIAKKYGNNGFEGNITLNFQGAAGQSFGAFNLDGMTLHLQGEANDYVGKGMNGGEIVI
VPHPQASFAPEDNVIIGNTCLYGATGGNLYANGRAGERFAVRNSVGKAVIEGAGDHCCEY
MTGGVIVVLGPVGRNVGAGMTGGLAYFLDEVGDLPEKINPEIITLQRITASKGEEQLKSL
ITAHVEHTGSPKGKAILANWSDYLGKFWQAVPPSEKDSPEANGDVSLTGEKTLTSV

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
2 L-glutamate + 2 oxidized ferredoxin = L- glutamine + 2-oxoglutarate + 2 reduced ferredoxin

# Drug_Target_3_SwissProt_ID:
P55038

# Drug_Target_3_SwissProt_Name:
GLTS_SYNY3

# Drug_Target_3_Synonyms:
EC 1.4.7.1
FD-GOGAT

# Drug_Target_3_Theoretical_pI:
5.53

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB02926
